Celgene joins collaborative multiple myeloma research project

Celgene has launched a new initiative called the Myeloma Genome Project alongside the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences.

The initiative aims to compile the largest ever dataset of high-quality genomic and clinical data to identify distinct molecular disease segments within multiple myeloma, allowing the partners to advance the diagnosis, prognosis and treatment of this form of cancer.

Additionally, the project will look at minor translocation and mutational groups that are often poorly described due to small sample numbers in limited datasets, with 2,161 patients for whom whole exome sequencing, whole genome sequencing, targeted panel sequencing and expression data from RNA sequencing and gene expression arrays are available having already been identified.

By integrating these diverse databases, it will be possible to identify genetic information that may inform clinical targets for therapy and facilitate the development of new testing methods.

Dr Rob Hershberg, executive vice-president and chief scientific officer at Celgene, said: "Understanding the various subgroups within multiple myeloma that exhibit distinct pathogenesis and clinical behaviour is critical when looking to advance new therapies, particularly when considering a targeted approach."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.